Tag: non hodgkin lymphoma (nhl) market forecast

  • Insights into the Future Growth Potential of the Non Hodgkin Lymphoma (NHL) Market 2024-2033

    Insights into the Future Growth Potential of the Non Hodgkin Lymphoma (NHL) Market 2024-2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Expected Expansion Rate of the Non Hodgkin Lymphoma (NHL) Market in the 2024-2033 Forecast?

    The market size for non-hodgkin lymphoma (nhl) has been progressing robustly over the past few years. The said market is expected to surge from $9.34 billion in 2023 to $10.23 billion in 2024, with a compound annual growth rate (CAGR) pegged at 9.4%. The historic growth could be ascribed to the rise in the incidence of nhl, advancements in diagnostic procedures, chemotherapy, and immunotherapy, developments in clinical research and drug creation, as well as enhanced survival rates.

    The market size for non-hodgkin lymphoma (nhl) is projected to experience robust growth in the coming years, reaching $14.13 billion in 2028 with a compound annual growth rate (CAGR) of 8.4%. Several factors are predicted to fuel this growth over the forecast period, such as an increase in the aging population, advances in targeted treatments, innovations in immunotherapy, the use of precision medicine approaches, and heightened awareness leading to early detection. The forecast period is also expected to see the rising popularity of biosimilars, the integration of next-generation sequencing, the adoption of car-t cell therapies, the introduction of new chemotherapy agents, as well as a focus on real-world evidence and outcomes research.

    Claim Your Free Sample of the Global Non Hodgkin Lymphoma (NHL) Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

    What Factors Are Catalyzing the Growth of the non hodgkin lymphoma (nhl) Market?

    The notable extent of non-Hodgkin lymphoma is predicted to drive the expansion of the non-Hodgkin lymphoma market. This type of cancer emerges within the lymphatic system, which forms a critical part of the immune system. The extent of this disease is gauged by how many people in a given population are diagnosed or living with it at a specific time period. Treating non-Hodgkin lymphoma improves the prognosis for those diagnosed with it, as it focuses on managing and eliminating cancer cells. For instance, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma represents 4% of all cancers, and in 2023, about 80,550 Americans, including 44,880 males and 35,670 females would be affected by it. The society also predicted around 20,180 deaths due to this cancer in 2023. In May 2022, the Canadian Cancer Society, a nationwide cancer charity in Canada, revealed that non-Hodgkin lymphoma would be diagnosed in 11,400 Canadians in 2022, causing the death of 3,000 Canadians. Hence, the considerable prevalence of non-Hodgkin lymphoma is propelling the non-Hodgkin lymphoma market.

    Which Segments Are Important in the Non Hodgkin Lymphoma (NHL) Market Landscape?

    1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

    2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

    3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

    5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

    What Are the Groundbreaking Trends in the Non Hodgkin Lymphoma (NHL) Market?

    The surge in advancements related to drug innovation is a rising trend in the non-Hodgkin lymphoma market. The industries involved are placing their focus on product innovation to maintain their market standing. Genentech Inc., a biotech company based in the U.S., for example, got approval from the FDA for Lunsumio, a pioneering bispecific antibody for relapsed or refractory follicular lymphoma treatment, in December 2022. This antibody is a new category of fixed-duration immunotherapy for cancer and is easily accessible as a ready off-the-shelf treatment, eliminating waiting time. The FDA’s approval of Lunsumio was a result of encouraging outcomes from the Lunsumio Phase II GO29781 study on individuals with severely pretreated FL, particularly those with rapid disease advancement or resistance to previous treatments.

    Order Now for Fast Delivery of Your Non Hodgkin Lymphoma (NHL) Market Report!

    https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

    What Are the Key Regions Powering Growth in the Non Hodgkin Lymphoma (NHL) Market?

    North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Non Hodgkin Lymphoma (NHL) Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the non hodgkin lymphoma (nhl) market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Non Hodgkin Lymphoma (NHL) Market Include

    1. Non Hodgkin Lymphoma (NHL) Market Executive Summary

    2. Non Hodgkin Lymphoma (NHL) Market Segments

    3. Non Hodgkin Lymphoma (NHL) Market Size And Template Market Growth Rate

    4. Key Non Hodgkin Lymphoma (NHL) Market Trends

    5. Major Non Hodgkin Lymphoma (NHL) Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market

    26. Top Non Hodgkin Lymphoma (NHL) Companies

    27. Non Hodgkin Lymphoma (NHL) Market Opportunities And Strategies

    28. Non Hodgkin Lymphoma (NHL) Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Premium Cosmetics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/premium-cosmetics-global-market-report

    Cosmetics And Personal Care Stores Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cosmetics-and-personal-care-stores-global-market-report

    Cosmetics And Personal Care Packaging Equipment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cosmetics-and-personal-care-packaging-equipment-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Global Non Hodgkin Lymphoma (NHL) Market Analysis 2024: Size, Share, And Key Trends

    Global Non Hodgkin Lymphoma (NHL) Market Analysis 2024: Size, Share, And Key Trends

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    As per The Business Research Company’s Non Hodgkin Lymphoma (NHL) Global Market Report 2024, the non-Hodgkin lymphoma (NHL) market is expected to show significant growth in the forecast period.

    The non-Hodgkin lymphoma (NHL) market has witnessed strong growth in recent years, driven by factors such as increased incidence of NHL, advancements in diagnostics, chemotherapy, and immunotherapy, and improved survival rates. The market, valued at $9.34 billion in 2023, is projected to reach $10.23 billion in 2024, with a compound annual growth rate (CAGR) of 9.4%. This growth is expected to continue in the forecast period, reaching $14.13 billion by 2028, with a CAGR of 8.4%.

    Rising Geriatric Population Driving Market Growth

    One of the key drivers of growth in the NHL market is the rising geriatric population. The geriatric population, defined as individuals aged 65 or older, has a higher incidence of NHL, emphasizing the need for specialized care and treatment for elderly individuals facing this hematological malignancy. With the global geriatric population expected to reach 2.1 billion by 2050, the demand for NHL treatments is expected to rise significantly.

    View More On The Non Hodgkin Lymphoma (NHL) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

     Advancements in Drug Innovations Revolutionizing Treatment Options

    Advancements in drug innovations are a key trend in the NHL market, with companies focusing on innovating new products to sustain their position in the market. For example, Genentech Inc. received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody represents a new class of fixed-duration cancer treatment immunotherapy, offering a readily available and off-the-shelf treatment option for patients.

    Acquisitions Expanding Product Portfolios

    Acquisitions are also shaping the NHL market, with companies acquiring technologies to broaden their product portfolios. For example, AstraZeneca PLC acquired TeneoTwo Inc., a biotechnology company focusing on oncology drug development. This acquisition will strengthen AstraZeneca’s oncology portfolio, adding a pipeline phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma.

    Market Segmentation and Regional Outlook

    The NHL market is segmented by type, treatment, route of administration, distribution channel, and end-users. By region, North America was the largest market in 2023, with Asia-Pacific expected to be the fastest-growing region during the forecast period.

    Request A Sample Of The Global Non Hodgkin Lymphoma (NHL) Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=10676&type=smp